GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (FRA:1GDA) » Definitions » Additional Paid-In Capital

Zevra Therapeutics (FRA:1GDA) Additional Paid-In Capital : €437.97 Mil(As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics Additional Paid-In Capital?


Zevra Therapeutics's quarterly additional paid-in capital increased from Sep. 2023 (€391.80 Mil) to Dec. 2023 (€433.43 Mil) and increased from Dec. 2023 (€433.43 Mil) to Mar. 2024 (€437.97 Mil).

Zevra Therapeutics's annual additional paid-in capital increased from Dec. 2021 (€351.31 Mil) to Dec. 2022 (€411.84 Mil) and increased from Dec. 2022 (€411.84 Mil) to Dec. 2023 (€433.43 Mil).

Zevra Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Zevra Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics Additional Paid-In Capital Chart

Zevra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 154.13 157.88 351.31 411.84 433.43

Zevra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 376.20 373.93 391.80 433.43 437.97

Zevra Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Zevra Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Zevra Therapeutics (FRA:1GDA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (FRA:1GDA) » Definitions » Additional Paid-In Capital
Comparable Companies
VSTM STRO APLT STOK ALLK AKBA GLUE LYRA ATNM IKNA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ZVRA:USA 1GDA:Germany
Address
1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747
Website
https://www.zevra.com
Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.

Zevra Therapeutics (FRA:1GDA) Headlines

No Headlines